Par responds to Searle Flagyl look-alike suit
Par said that the Aug. 20 New Jersey District Court decision prohibiting it from marketing a look-alike version of metronidazole "will have no effect on its operations." Par said that total sales of the Flagyl look-alike generic metronidazole "were less than $100,000." Par will continue to sell a non-look-alike version of metronidazole that has been on the market for more than two years.
You may also be interested in...
Novavax aims to recruit 10,000 subjects in the UK, and will include a flu vaccination co-administration for some participants.
Accord has launched its first monoclonal antibody biosimilar and fourth biosimilar overall, introducing in the UK the Zercepac version of trastuzumab developed by China’s Shanghai Henlius Biotech.
Alvogen sister company Alvotech is continuing to extend its network of commercial partners by expanding its partnership with DKSH, a Swiss market expansion services group, for the commercialization of six biosimilars in Asian markets.